According to Mark Jensen, Chair and member of the Special Committee of the Board of Directors of 23andMe, Regeneron is offering to keep all of the former company's employees.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

Regeneron Pharmaceuticals said it will acquire "substantially all" of 23andMe's assets. The genetic testing company filed for Chapter 11 bankruptcy protection in March.

In its own statement, 23andMe said that Regeneron had offered jobs to all of the employees in the business units that it was acquiring.Mark Jensen, chair and member of the special committee of the ...

Both companies vowed that Regeneron is committed to comply with 23andMe's privacy policies, should the purchase be approved 23andMe filed for bankruptcy in March 2025, four months after laying off ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

According to Mark Jensen, Chair and member of the Special Committee of the Board of Directors of 23andMe, Regeneron is offering to keep all of the former company's employees.

By Michelle Chapman, The Associated Press. Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 ...